Why the IMPACT-TD findings matter for Teva shareholders

Teva Pharmaceutical Industries (NYSE:TEVA) has released new real world data from its 3 year IMPACT-TD Registry, highlighting missed and delayed diagnoses of tardive dyskinesia in patients with mood disorders, especially younger adults.

For investors, this clinically focused update puts a spotlight on unmet need in tardive dyskinesia care, an area linked to Teva’s movement disorder portfolio. It also raises questions about how diagnosis patterns might influence long term treatment demand.

Teva’s latest IMPACT-TD data arrives at a time when momentum in the stock has been firm, with a 14.12% year to date share price return and a very large 3 year total shareholder return of 388.52%. This suggests investors are reassessing both growth prospects and risks around its central nervous system and movement disorder franchises.

If this kind of real world clinical update interests you, it can be useful to see what is happening across the wider healthcare and neurology space, including companies using AI in treatment and diagnosis, by checking out 39 healthcare AI stocks

With Teva trading at $35.32, sitting at a discount to an average analyst price target of $41.27 and an estimated intrinsic value, the key question is whether this gap reflects mispricing or if markets already recognise potential future developments.

Most Popular Narrative: 12.3% Undervalued

Teva’s most followed valuation narrative pegs fair value at about $40.27 per share, compared with the last close at $35.32. This frames the stock as trading below that estimate while putting a spotlight on earnings power and margins.

Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.

Curious what has to happen in neuroscience, immunology, biosimilars, and margins to back up that fair value gap? The growth, mix shift, and earnings assumptions behind this narrative are far from ordinary. The full breakdown sets out a detailed playbook for how Teva could get there.

Result: Fair Value of $40.27 (UNDERVALUED)

However, for this narrative to hold, Teva still needs to manage its US$15b plus net debt and avoid setbacks or slower uptake across its biosimilars and key CNS drugs.

Another View on Teva’s Valuation

The fair value story from the narrative points to Teva as undervalued, but the current P/E of 26.3x paints a tougher picture. It sits well above the estimated fair ratio of 23.9x, the US Pharmaceuticals average of 15.4x, and a 19.5x peer average, which implies less margin for error if growth stumbles. So which signal do you put more weight on?

Next Steps

The mixed messages on value, growth, and balance sheet risk make this a stock you may want to assess directly and quickly so you are comfortable with your stance. Then weigh the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you miss chances that could fit your goals even better, so broaden your watchlist using focused, data rich screeners.

• Target resilient cash generators that still look attractively priced by scanning the 46 high quality undervalued stocks and comparing their fundamentals with what you already own.
• Prioritise strength and staying power by filtering for companies in the solid balance sheet and fundamentals stocks screener (46 results) that may handle pressure without stretching their finances.
• Spot opportunities the crowd might be overlooking by scouting the screener containing 22 high quality undiscovered gems before attention and trading volumes catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.